Promising new combo aims to extend life in rare, Tough-to-Treat cancer
NCT ID NCT07337447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs (zimberelimab and domvanalimab) to standard chemotherapy (FOLFIRI) helps people with a rare, fast-growing neuroendocrine cancer live longer. About 122 adults whose cancer has worsened after first treatment will take part. The goal is to see if the combination improves survival at 12 months compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NEUROENDOCRINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens Picardie
Amiens, France
Contact
Contact
-
CHU Avicenne APHP
Bobigny, France
Contact
Contact
-
CHU Caen Normandie
Caen, France
Contact
Contact
-
CHU Dijon
Dijon, France
Contact
Contact
-
CHU Montpellier - Hôpital Saint Eloi
Montpellier, France
Contact
Contact
-
CHU Rouen
Rouen, France
Contact
Contact
-
CHU Timone
Marseille, France
Contact
Contact
-
CHU de Bordeaux - Hôpital Haut-Leveque
Pessac, France
Contact
Contact
-
CHU de Grenoble
Grenoble, France
Contact
Contact
-
CHU de Poitiers
Poitiers, France
Contact
Contact
-
Centre Oscar Lambret
Lille, France
Contact
Contact
-
Centre Paul Strauss
Strasbourg, France
Contact
Contact
-
HEGP
Paris, France
Contact
Contact
-
Hôpital Beaujon
Clichy, France
Contact
Contact
-
Hôpital Henri MONDOR
Créteil, France
Contact
Contact
-
Hôpital Robert Debré, CHU de Reims
Reims, France
Contact
Contact
-
Hôpital Saint Antoine APHP
Paris, France
Contact
Contact
-
Hôpital Saint Louis APHP
Paris, France
Contact
Contact
-
Institut Gustave Roussy
Villejuif, France
Contact
Contact
-
Institut Paoli Calmettes
Marseille, France
Contact
Contact
-
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, France
Contact
Contact